Cargando…
Myasthenia gravis, respiratory function, and respiratory tract disease
Myasthenia gravis (MG) is characterized by muscle weakness caused by autoantibodies that bind to the postsynaptic membrane at the neuromuscular junction and impair acetylcholine receptor function. Weakness of respiratory muscles represents the most severe MG manifestation, and 10–15% of all patients...
Autor principal: | Gilhus, Nils Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132430/ https://www.ncbi.nlm.nih.gov/pubmed/37101094 http://dx.doi.org/10.1007/s00415-023-11733-y |
Ejemplares similares
-
Advances and challenges in the treatment of myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2021) -
Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011) -
Immunoactive treatment for myasthenia gravis; a Chinese experience
por: Gilhus, Nils Erik
Publicado: (2020) -
User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022) -
Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)